BMY241227C47000
- 10.60
- 0.000.00%
Bristol-Myers Squibb Newsroom
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Bristol-Myers Squibb Says Phase 3 Trials of Sotyktu in Psoriatic Arthritis Meets Endpoints
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Express News | Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile
Express News | Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
Express News | Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Express News | Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $70
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
Express News | Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now?
Unusual Options Activity: NVT, IDXX and Others Attract Market Bets, NVT V/OI Ratio Reaches 238.0